Gurnet Point Capital And Patient Square Capital Complete Their Acquisition Of Radius Health, Inc.
Acquiring Company
Patient Square Capital
Acquired Company
Radius
Menlo ParkInformation TechnologyFinancial ServicesSoftwareMobileHealth CareFinanceInvestment ManagementBiotechnologyVenture CapitalBiotechnologyHealth CareMedicalTherapeuticsPharmaceuticalDescription
Gurnet Point Capital (“Gurnet Point”) and Patient Square Capital (“Patient Square”) announced today the completion of their acquisition of Radius Health, Inc. (Nasdaq: RDUS) (“Radius”). Radius is a global, commercial-stage biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health and neuro-orphan diseases. Radius’ lead product, TYMLOS® (abaloparatide) was launched in the U.S. in 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Quick answer
Patient Square Capital and Gurnet Point Capital are acquiring Radius, announced August 15, 2022. Patient Square Capital is based in Menlo Park, California, United States.
- How much did Patient Square Capital pay for Radius?
- The deal value was not disclosed.
- What does Patient Square Capital do?
- Patient Square Capital is a dedicated health care investment firm that partners with best-in-class management teams whose products, services and technologies improve health.
- Where are Patient Square Capital and Radius based?
- Patient Square Capital is based in Menlo Park, California, United States.
- Who are the decision-makers at Patient Square Capital?
- Fundz holds 2 contacts at Patient Square Capital. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Financial Services and Mobile
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Bristol Myers Squibb And Turning Point Therapeutics Announce Expiration Of Hsr Act Waiting Period And Clearance From Federal Cartel Office Of Germany Related To Pending Acquisition Of Turning Point Therapeutics (August 16, 2022)
- Bristol Myers Squibb Completes Acquisition Of Turning Point Therapeutics, Expanding Precision Oncology Portfolio (August 17, 2022)
- Md Office Solutions, Llc, Acquires Antigua Medical Services, Llc; A Cardiac Mobile Imaging Company In Arizona (August 17, 2022)
- Pfizer To Acquire Global Blood Therapeutics For $5.4 Billion To Enhance Presence In Rare Hematology, $5.4B (August 8, 2022)
- Clearlake Capital And Ta Associates Complete Acquisition Of Kofax (July 25, 2022)
- Rocket Pharmaceuticals To Acquire Renovacor, Extending Leadership In Aav-Based Cardiac Gene Therapy (September 20, 2022)
Who to call at Patient Square Capital, and when
When Patient Square Capital changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Patient Square Capital raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Patient Square Capital, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Patient Square Capital. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Patient Square Capital makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Radius?
Radius was acquired by Patient Square Capital, based in Menlo Park. The deal was reported on August 15, 2022. Patient Square Capital is a dedicated health care investment firm that partners with best-in-class management teams whose products, services and technologies improve health. Patient Square Capital is privately held and operates in Information Technology.
When did Patient Square Capital acquire Radius?
Patient Square Capital's acquisition of Radius was reported on August 15, 2022. Gurnet Point Capital (“Gurnet Point”) and Patient Square Capital (“Patient Square”) announced today the completion of their acquisition of Radius Health, Inc. (Nasdaq: RDUS) (“Radius”). Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Radius do?
Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, neuro- orphan diseases, and oncology. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.